Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 17.82 EUR -0.45% Market Closed
Market Cap: 518.1m EUR
Have any thoughts about
Medincell SA?
Write Note

Relative Value

The Relative Value of one MEDCL stock under the Base Case scenario is 8.77 EUR. Compared to the current market price of 17.82 EUR, Medincell SA is Overvalued by 51%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MEDCL Relative Value
Base Case
8.77 EUR
Overvaluation 51%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
25
vs Industry
6
Median 3Y
25
Median 5Y
32.6
Industry
2.6
Forward
15.9
vs History
vs Industry
Median 3Y
-7.8
Median 5Y
-7.8
Industry
23
Forward
-49.4
vs History
vs Industry
Median 3Y
-10.4
Median 5Y
-11.4
Industry
17.8
vs History
vs Industry
Median 3Y
-10.6
Median 5Y
-14
Industry
25.4
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-10.1
Industry
2.2
vs History
28
vs Industry
6
Median 3Y
26.4
Median 5Y
31.5
Industry
2.8
Forward
17
vs History
30
vs Industry
3
Median 3Y
35.6
Median 5Y
46.4
Industry
5.4
vs History
vs Industry
Median 3Y
-10.6
Median 5Y
-10.6
Industry
13.7
Forward
88.1
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-9.9
Industry
17.2
Forward
1 208.8
vs History
vs Industry
Median 3Y
-10.9
Median 5Y
-12.5
Industry
16.5
vs History
vs Industry
Median 3Y
-10
Median 5Y
-11.9
Industry
19.3
vs History
3
vs Industry
6
Median 3Y
12.9
Median 5Y
14
Industry
2

Multiples Across Competitors

MEDCL Competitors Multiples
Medincell SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Medincell SA
PAR:MEDCL
518m EUR 57.4 -20.7 -28.8 -26.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.5B USD 18.5 90.4 48.6 54.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.4 27.8
US
Johnson & Johnson
NYSE:JNJ
364.1B USD 4.2 24.8 12 15.6
US
Merck & Co Inc
NYSE:MRK
248.4B USD 3.9 20.5 10.4 12.4
CH
Roche Holding AG
SIX:ROG
208.5B CHF 3.6 18.1 10.2 12.1
CH
Novartis AG
SIX:NOVN
181.2B CHF 4.2 12.6 10 14.9
UK
AstraZeneca PLC
LSE:AZN
159.6B GBP 4.1 31.5 169.4 253.8
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
FR
Medincell SA
PAR:MEDCL
Average P/E: 33.3
Negative Multiple: -20.7
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
90.4
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
24.8
-22%
US
Merck & Co Inc
NYSE:MRK
20.5
7 336%
CH
Roche Holding AG
SIX:ROG
18.1
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A
EV/EBIT Multiple
EBIT Growth
FR
Medincell SA
PAR:MEDCL
Average EV/EBIT: 2 075.6
Negative Multiple: -26.5
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
212%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
DK
Novo Nordisk A/S
CSE:NOVO B
27.8
85%
US
Johnson & Johnson
NYSE:JNJ
15.6
29%
US
Merck & Co Inc
NYSE:MRK
12.4
695%
CH
Roche Holding AG
SIX:ROG
12.1
27%
CH
Novartis AG
SIX:NOVN
14.9
54%
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
IE
E
Endo International PLC
LSE:0Y5F
587.7
N/A

See Also

Discover More
Back to Top